Ah, I see. It sounds to me like the issue is that there's not enough of a market to attract the interest of another company to get over the initial fixed costs

Ah, I see. It sounds to me like the issue is that there's not enough of a market to attract the interest of another company to get over the initial fixed costs to get the drug approved. Seems like a possible reform would be to streamline the approval process for generics to make this easier.